Decheng Capital Global Life Sciences Fund IV, L.P. - 29 Jan 2024 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role
10%+ Owner
Signature
Decheng Capital Global Life Sciences Fund IV, L.P., By Decheng Capital Management IV (Cayman), LLC, its General Partner, By /s/ Xiangmin Cui, Manager
Issuer symbol
CGON
Transactions as of
29 Jan 2024
Net transactions value
+$7,600,000
Form type
4
Filing time
31 Jan 2024, 16:17:10 UTC
Previous filing
24 Jan 2024
Next filing
12 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGON Common Stock Conversion of derivative security +3,628,198 +390% 4,558,812 29 Jan 2024 Direct F1, F2
transaction CGON Common Stock Purchase $7,600,000 +400,000 $19.00* 400,000 29 Jan 2024 By Decheng Capital Global Healthcare Fund (Master), LP F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGON Series C Preferred Stock Conversion of derivative security -8,644,891 -100% 0 29 Jan 2024 Common Stock 906,648 Direct F1, F2
transaction CGON Series E Preferred Stock Conversion of derivative security -21,547,685 -100% 0 29 Jan 2024 Common Stock 2,259,851 Direct F1, F2
transaction CGON Series F Preferred Stock Conversion of derivative security -4,402,320 -100% 0 29 Jan 2024 Common Stock 461,701 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Decheng Capital Global Life Sciences Fund IV, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock at the holder's election and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering.
F2 These securities are held directly by Decheng Capital Global Life Sciences Fund IV, L.P. ("Fund IV"). Decheng Capital Management IV (Cayman), LLC ("GP IV") is the general partner of Fund IV. Xiangmin Cui is the manager of GP IV. Each of Fund IV, GP IV and Dr. Cui may be deemed to beneficially own the securities held by Fund IV. Each of GP IV and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.
F3 These securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healthcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the manager of Healthcare GP. Each of Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Each of Healthcare GP and Dr. Cui disclaims beneficial ownership of these securities, except to the extent of its or his proportionate pecuniary interest therein.